Phase 3 LATITUDE Atlas data presented at EADV 2026 showed higher rates of complete and near-complete skin clearance with zasocitinib compared with deucravacitinib.
|Articles|May 1, 2004
Dermatology Life Quality Indexprovides different information from PASI
Washington - The Dermatology Life Quality Index (DLQI) is a widely used and validated measure of patient-reported outcomes in psoriasis. Unlike the Psoriasis Area Severity Index (PASI) score, a well-established measure of a patient's disease activity where each area of the body is weighted proportionally to the surface area covered, the DLQI is more heavily influenced by areas of the body that are readily visible, such as the head and lower extremities. "Therefore, the DLQI may provide information regarding outcomes beyond that described by the PASI score," said Alexa B. Kimball, M.D., M.P.H., assistant professor of dermatology at Stanford University.
Advertisement
Advertisement
Related to this article
Day 2 of EADV 2026 highlighted new findings involving GLP-1–associated nail changes, long-term atopic dermatitis control, emerging therapies, alopecia, and hidradenitis suppurativa.
According to data presented at EADV, at week 16 of the phase 2 study, 47.8% to 62.5% of adults receiving tilrekimig achieved EASI 75 across doses, compared with 9.1% to 19.9% with placebo.
AbbVie reports F-VASI 75 of 55.1% in Viti-Up-1 and 47.4% in Viti-Up-2 at week 76 among patients continuing upadacitinib, with numerically higher responses alongside NB-UVB.
A new report from the National Eczema Association (NEA) found systemic corticosteroids were filled more often than dupilumab, and 13% of Americans live in counties without a dermatology or allergy/immunology practitioner.
Real-world EADV 2026 data suggest autonomous AI could increase dermatology capacity while maintaining high sensitivity for invasive skin cancers.
Up to 72% of tulisokibart-treated patients achieved HiSCR50 at week 16 vs 35% with placebo, the first positive phase 2 anti-TL1A data in dermatology.
Treatment success reached 56.7% and total lesions fell 71.8% with up to 52 weeks of oral denifanstat, with no adverse event-related discontinuations.
Advertisement
Advertisement
Trending on Dermatology Times
1
NEA Report Highlights Atopic Dermatitis Care Access Gaps by State
2
EADV 2026 Day 1: Late-Breaking Data, Emerging Therapies, and New Directions in Dermatology
3
Tulisokibart Meets Primary Endpoint in Phase 2b Hidradenitis Suppurativa Trial
4
Daxdilimab Shows Rapid, Significant Improvements in Discoid Lupus in Phase 2 Trial
5